In English | En español
Questions About Cancer? 1-800-4-CANCER

Childhood Hodgkin Lymphoma Treatment (PDQ®)

  • Updated: 04/08/2014

Table 2. Criteria Used for the Classification of Risk Groups in Childhood Hodgkin Lymphoma Clinical Trialsa

Trial Low Risk Intermediate Risk High Risk 
Children's Oncology Group
AHOD0031 [20]IA bulk or E; IB; IIA bulk or E; IIB; IIIA, IVA
AHOD0431 [21]IA, IIA with no bulk
AHOD0831 IIIB, IVB
C5942 [22]IA, IB, IIA with no bulk, no hilar nodes and <4 sitesIA, IB, IIA with bulk, hilar nodes or ≥4 sites; IIIIV
C59704 [23]IIB/IIIB with bulk, IV
P9425/P9426 [24]IA, IIA with no bulkIB, IIA, IIIA1 with bulk; IIIA2IIB, IIIB, IV
German Multicenter/Euronet
GPOH-HD 95; GPOH-HD 2002; PHL-C1 [4,25,26]1A/B, IIAIEA/B;IIEA; IIB; IIIAIIEB; IIIEA/B; IIIB; IV
Stanford/St. Jude/Dana-Farber Cancer Institute Consortium
HOD05 IB, IIIA, IA/IIA with E, ≥3 sites or bulk
HOD08 IA, IIA with no bulk, E and <3 sites
HOD99 IIB, IIIB, IV

E = extralymphatic.
aAdapted from Kelly.[19]

References

  1. Mauz-Körholz C, Hasenclever D, Dörffel W, et al.: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28 (23): 3680-6, 2010.  [PUBMED Abstract]

  2. Kelly KM: Management of children with high-risk Hodgkin lymphoma. Br J Haematol 157 (1): 3-13, 2012.  [PUBMED Abstract]

  3. Friedman DI, Wolden S, Constine L, et al.: AHOD0031: A phase III study of dose intensive therapy for intermediate risk Hodgkin lymphoma: a report from the Children’s Oncology Group. [Abstract] Blood 116 (22): A-766, 2010. 

  4. Keller FG, Nachman J, Constine L: A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL). [Abstract] Blood 116 (21): A-767, 2010. 

  5. Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (18): 3765-71, 2002.  [PUBMED Abstract]

  6. Kelly KM, Sposto R, Hutchinson R, et al.: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117 (9): 2596-603, 2011.  [PUBMED Abstract]

  7. Schwartz CL, Constine LS, Villaluna D, et al.: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114 (10): 2051-9, 2009.  [PUBMED Abstract]

  8. Schellong G, Pötter R, Brämswig J, et al.: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17 (12): 3736-44, 1999.  [PUBMED Abstract]

  9. Dörffel W, Lüders H, Rühl U, et al.: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215 (3): 139-45, 2003 May-Jun.  [PUBMED Abstract]